Gefitinib (ZD1839, Iressa®) in non-small-cell lung cancer: A review of clinical trials from a daily practice perspective

Fundamental and Clinical Pharmacology

Volumn 19, Issue 3, 2005, Pages 385-393

  Barlési, Fabrice ^a   Tchouhadjian, Cécile ^a   Doddoli, Christophe ^a   Villani, Patrick ^a   Greillier, Laurent ^a   Kleisbauer, Jean Pierre ^a   Thomas, Pascal ^a   Astoul, Philippe ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Clinical trial; Epidermal growth factor receptor; Gefitinib; Lung cancer; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM;

ACNE; AREA UNDER THE CURVE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; HUMAN; INTERSTITIAL PNEUMONIA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SKIN TOXICITY; SYSTEMATIC REVIEW;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DATABASES, FACTUAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 20044362281     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00323.x     Document Type: Review

References (57)

1. Coleman M.P., Gatta G., Verdecchia A. et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann. Oncol. (2003) 14 (Suppl. 5) 128-149.
2. Pfister D.G., Johnson D.H., Azzoli C.G. et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. (2004) 22 330-353.
3. Rusch V., Baselga J., Cordon-Cardo C. et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. (1993) 53 (Suppl.) 2379-2385.
4. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. (1997) 3 515-522.
5. Fontanini G., De Laurentiis M., Vignati S. et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. (1998) 4 241-249.
6. Brabender J., Danenberg K.D., Metzger R. et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res. (2001) 7 1850-1855.
7. Ranson M., Hammond L.A., Ferry D. et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. (2002) 20 2240-2250.
8. Herbst R.S., Maddox A.M., Rothenberg M.L. et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-striall-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. (2002) 20 3815-3825.
9. Baselga J., Rischin D., Ranson M. et al. Phase I safety, pharmacokmetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. (2002) 20 4292-4302.
10. Nakagawa K., Tamura T., Negoro S. et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('tressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. (2003) 14 922-930.
11. LoRusso P.M., Herbst R.S., Rischin D. et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res. (2003) 9 2040-2048.
12. Albanell J., Rojo F., Averbuch S. et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. (2002) 20 110-124.
13. Fukuoka M., Yano S., Giaccone G. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 21 2237-2246.
14. Kris M.G., Natale R.B., Herbst R.S. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290 2149-2158.
15. Cohen M.H., Williams G.A., Sridhara R. et al. United States Food and Drug Administration Drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. (2004) 10 1212-1218.
16. Giaccone G., Herbst R.S., Manegold C. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. (2004) 22 777-784.
17. Herbst R.S., Giaccone G., Schiller J.H. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. (2004) 22 785-794.
18. Simon G.R., Ruckdeschel J.C., Williams C. et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control (2003) 10 388-395.
19. Pallis A.G., Mavroudis D., Androulakis N. et al. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer (2003) 40 301-307.
20. Santoro A., Cavina R., Latteri F. et al. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann. Oncol. (2004) 15 33-37.
21. Hainsworth J.D., Mainwaring M.G., Thomas M. et al. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. Clin. Lung Cancer (2003) 4 347-355.
22. Jänne P.A., Gurubhagavatula S., Yeap B.Y. et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839. 'Iressa') on an expanded access study. Lung Cancer (2004) 44 221-230.
23. Haringhuizen A., van Tinteren H., Vaessen H.F., Baas P., van Zandwijk N. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann. Oncol. (2004) 15 786-792.
24. Kaneda H., Tamura K., Kurata T., Uejima H., Nakagawa K., Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer (2004) 46 247-254.
25. Herbst R.S., LoRusso P.M., Purdom M., Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin. Lung Cancer (2003) 4 366-369.
26. van den Bent MJ. The role of chemotherapy in brain metastases. Eur. J. Cancer (2003) 39 2114-2120.
27. Cappuzzo F., Ardizzoni A., Soto-Parra H. et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer (2003) 41 227-231.
28. Cappuzzo F., Calandri C. Bartolini S., Crino L. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br. J. Cancer (2003) 89 246-247.
29. Katz A., Zalewski P. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. Br. J. Cancer (2003) 89 (Suppl. 2) S15-S18.
30. Hotta K., Kiura K., Ueoka H. et al. Effect of gefitinib (Iressa, ZD1839) on brain metastases in patients with advanced non-small cell lung cancer. Lung Cancer (2004) 46 255-261.
31. Cappuzzo F., Bartolini S., Ceresoli G.L. et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br. J. Cancer (2004) 90 82-86.
32. Gridelli C., Maione P., Castaldo V., Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br. J. Cancer (2003) 89 1827-1829.
33. Stahel R., Rossi A., Petruzelka L. et al. Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. Br. J. Cancer (2003) 89 (Suppl. 2). S19-S23.
34. Miller V.A., Kris M.G., Shah N. et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. (2004) 22 1103-1109.
35. West H., Franklin W.A., Gumerlock P.H. et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings 22, Abstract 7014.
36. Cohen E.E., Rosen F., Stadler W.M. et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2003) 21 1980-1987.
37. Inoue A., Saijo Y., Maemondo M. et al. Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 361 137-139.
38. Raben D., Helfrich B., Ciardiello F., Bunn P.A. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer (2003) 41 (Suppl. 1) S15-S22.
39. Cappuzzo F., Gregore V., Rossi E. et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. (2003) 21 2658-2663.
40. Suzuki T., Nakagawa T., Endo H. et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer (2003) 42 35-41.
41. Bianco R., Shin I., Ritter C.A. et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the anti-tumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 22 2812-2822.
42. Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350 2129-2139.
43. Paez J.G., Janne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304 1497-1500.
44. Cappuzzo F., Magrini E., Ceresoli G.L. et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (2004) 96 1133-1141.
45. Dancey J.E., Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet (2003) 362 62-64.
46. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J. Clin. Oncol. (2004) 22 759-761.
47. Sirotnak P.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6 4885-4892.
48. Ciardiello F., Caputo R., Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6 2053-2063.
49. Gatzemeier U., Rosell R., Ramlau R. Cetuximab (C225) in combination with cisplatin/vinorelbine alone in the first line treatment of patients with EGFR positive advanced NSCLC. J. Clin. Oncol. (2003) ASCO Annual Meeting Proceedings 22. Abstract 2582.
50. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344 783-792.
51. Betensky R.A., Louis D.N., Cairncross J.G. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. (2002) 20 2495-2499.
52. Shepherd F.A., Pereira J., Ciuleanu T.E. et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings 22, Abstract 7022.
53. Gatzemeier U., Pluzanska A., Szczesna A. et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings 22, Abstract 7010.
54. Herbst R.S., Prager D., Hermann R. et al. TRIBUTE - a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings 22, Abstract 7011.
55. Rosell R., Daniel C., Ramlau R. et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings 22, Abstract 7012.
56. Douillard J.-Y., Giaccone G., Horai T. et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL I). J. Clin. Oncol. (2002) ASCO Annual Meeting Proceedings 21, Abstract 1195.
57. Natale R.B., Skarin A.T., Maddox A.-M. et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. J. Clin. Oncol. (2002) ASCO Annual Meeting Proceedings 21, Abstract 1167.